您的位置: 专家智库 > 资助详情>国家自然科学基金(30672482)

国家自然科学基金(30672482)

作品数:4 被引量:39H指数:3
相关作者:何琪杨徐榕李咏李电东邹珊珊更多>>
相关机构:中国医学科学院北京协和医学院更多>>
发文基金:国家自然科学基金“重大新药创制”科技重大专项国家重点基础研究发展计划更多>>
相关领域:医药卫生更多>>

文献类型

  • 3篇中文期刊文章

领域

  • 3篇医药卫生

主题

  • 2篇凋亡
  • 2篇多药
  • 2篇多药耐药
  • 2篇多药耐药性
  • 2篇细胞
  • 2篇细胞凋亡
  • 2篇耐药
  • 2篇耐药性
  • 1篇药理
  • 1篇药性
  • 1篇药药
  • 1篇人乳
  • 1篇人乳腺癌
  • 1篇人乳腺癌MC...
  • 1篇人乳腺癌MC...
  • 1篇乳腺
  • 1篇乳腺癌
  • 1篇中药
  • 1篇中药药理
  • 1篇肿瘤

机构

  • 2篇中国医学科学...

作者

  • 2篇何琪杨
  • 2篇徐榕
  • 1篇张秀敏
  • 1篇邹珊珊
  • 1篇李电东
  • 1篇李咏

传媒

  • 1篇药学学报
  • 1篇中国中西医结...
  • 1篇Biomed...

年份

  • 1篇2010
  • 1篇2009
  • 1篇2008
4 条 记 录,以下是 1-3
排序方式:
复方中药紫龙金克服肿瘤细胞多药耐药性的机制被引量:24
2010年
目的探讨中药紫龙金(Zilongjin,ZLJ)对多药耐药肿瘤细胞的作用机制。方法采用MTT法检测ZLJ对细胞增殖的影响;流式细胞术检测细胞周期以及罗丹明123的荧光强度变化;Western blot方法检测相关蛋白的表达变化。结果 ZLJ分别处理人乳腺癌MCF-7和MCF-7/DOX耐药细胞,以及人口腔上皮癌KB和KBV200耐药细胞。MTT法测定表明:ZLJ作用耐药和敏感细胞的IC50值相近,耐药细胞对ZLJ没有交叉耐药性;无论对敏感和耐药细胞,流式细胞术分析发现ZLJ阻断细胞于S期;ZLJ单独处理MCF-7/DOX和KBV200耐药细胞,可以微弱地降低其耐药性,分别与多柔比星(doxorubicin,DOX)和长春新碱(vincris-tine,VCR)合用,可以明显地增加DOX和VCR的活性;ZLJ处理耐药细胞MCF-7/DOX后,检测到细胞内耐药蛋白P-糖蛋白(P-glyco protein,P-gp)呈时间依赖性降低。Western blot检测表明,ZLJ的抑制作用是通过使凋亡标志蛋白PARP出现切割,启动凋亡通路实现的。结论中药ZLJ抑制耐药细胞增殖,没有交叉耐药性;其抑制作用与诱导细胞凋亡以及降低P-gp表达有关。
邹珊珊徐榕何琪杨
关键词:多药耐药性肿瘤细胞紫龙金细胞凋亡中药药理
SIRT1去乙酰化酶抑制剂引起人乳腺癌MCF-7耐药细胞凋亡的机制被引量:5
2008年
研究SIRT1去乙酰化酶抑制剂引起人乳腺癌MCF-7耐多柔比星(doxorubicin,DOX)细胞及其敏感细胞凋亡的机制。MTT法检测细胞生长抑制作用;Western blotting方法检测蛋白表达;DNA特异染料Hoechst 33342染色检测染色质凝集;Annexin V检测细胞凋亡;流式细胞仪测定细胞周期分布。结果表明,SIRT1去乙酰化酶抑制剂烟酰胺(nicotinamide,NAM)和Sirtinol对人乳腺癌细胞MCF-7敏感和耐药细胞表现出相同的生长抑制作用,但没有增强DOX活性的作用。NAM使MCF-7和MCF-7/DOX细胞阻滞在G2/M期。50 mmol.L-1NAM作用MCF-7细胞后,激活caspase凋亡通路,出现PARP、caspase-6、-7、-9切割片段,并且染色质发生凝集和Annexin V阳性细胞。而在MCF-7/DOX耐药细胞中,NAM作用24 h后,才开始出现PARP、caspase-6、-7切割片段,48 h后明显增加,可以检测到较多的细胞出现染色质凝集和Annexin V阳性细胞。SIRT1去乙酰化酶抑制剂对人乳腺癌MCF-7耐药细胞和敏感细胞均有相似的抑制作用,无交叉耐药性,其作用通过激活caspase凋亡通路实现。
李咏徐榕张秀敏李电东何琪杨
关键词:多药耐药性细胞凋亡人乳腺癌MCF-7细胞
Role of Prosurvival Molecules in the Action of Lidamycin toward Human Tumor Cells
2009年
Objective Lidamycin, an enediyne antibiotic, leads to apoptosis and mitotic cell death of human tumor cells at high and low concentrations. The reason why tumor cells have distinct responses to lidamycin remains elusive. This study was to elucidate if cellular prosurvival molecules are involved in these responses. Methods Cleavage of chromatin and DNA was observed by chromatin condensation and agarose gel electrophoresis. Accumulation of rhodamine 123 in lidamycin-treated cells was assayed by flow cytometry. Cell multinucleation was detected by staining with Hoechst 33342. Western blot and senescence-associated β-galactosidase (SA-β-gal) staining were used to analyze protein expression and senescence-like phenotype, respectively. Results SIRT1 deacetylase remained unchanged in 0.5 nmol/L lidamycin whereas cleavage occurred when apoptosis was induced by lidamycin. Increased FOXO3a, SOD-1 and SOD-2 expression and transient phosphorylation of ERK were detected after exposure of human hepatoma BEL-7402 cells to 0.5 nmol/L lidamycin. High expressions of SIRT1 and Akt were found in colon carcinoma HCT116 p53 knock-out cells exposed to lidamycin. Degradation of PARP and p53 by lidamycin as a substitute for SIRT1 and Akt was confirmed with caspase inhibitor Q-VD-OPh and proteasome inhibitor MG132. Resistance to lidamycin-induced DNA cleavage was observed in breast cancer doxorubicin-resistant MCF-7 cells. This was not induced by P-glycoprotein as no accumulation of rhodamine 123 was detected in the resistant cells following exposure to lidamycin. In contrast to sensitive MCF-7 cells, a lower multinucleation rate for the resistant cells was measured following exposure to equal concentrations of lidamycin. Conclusions Cellular prosurvival molecules, such as SIRTI, Akt, SOD-1, SOD-2 and other unknown factors can influence the action of lidamycin on human tumor cells.
A-JING YANG WEI-WEI SHI YONG LI ZHEN WANG RONG-GUANG SHAO DIAN-DONG LI QI-YANG HE
关键词:LIDAMYCIN
共1页<1>
聚类工具0